References
[1] C. Hill et al., “Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic,” Nat. Rev. Gastroenterol. Hepatol., vol. 11, no. 8, pp. 506–514, Aug. 2014, doi: 10.1038/nrgastro.2014.66.
[2] N. B. Kristensen, T. Bryrup, K. H. Allin, T. Nielsen, T. H. Hansen, and O. Pedersen, “Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials,” Genome Med., vol. 8, p. 52, May 2016, doi: 10.1186/s13073-016-0300-5.
[3] R. L. Day, A. J. Harper, R. M. Woods, O. G. Davies, and L. M. Heaney, “Probiotics: current landscape and future horizons,” Future Sci. OA, vol. 5, no. 4, p. FSO391, 2019, doi: 10.4155/fsoa-2019-0004.
[4] “Office of Dietary Supplements - Probiotics,” National Institutes of Health. https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/ (accessed Jun. 22, 2023).
[5] “Ferring Receives U.S. FDA Approval for REBYOTATM (fecal microbiota, live-jslm) – A Novel First-in-Class Microbiota-Based Live Biotherapeutic,” Ferring Pharmaceuticals USA, Nov. 30, 2022. https://ferringusa.com/?press=ferring-receives-u-s-fda-approval-for-rebyota-fecal-microbiota-live-jslm-a-novel-first-in-class-microbiota-based-live-biotherapeutic (accessed Jun. 22, 2023).
[6] “FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection,” FDA, Apr. 28, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-orally-administered-fecal-microbiota-product-prevention-recurrence-clostridioides (accessed Jun. 22, 2023).
[7] “Small Entity Compliance Guide: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements,” U.S. Food and Drug Administration, May 13, 2023. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-current-good-manufacturing-practice-manufacturing-packaging-labeling (accessed Jun. 22, 2023).
[8] A. Zawistowska-Rojek, T. Zaręba, and S. Tyski, “Microbiological Testing of Probiotic Preparations,” Int. J. Environ. Res. Public. Health, vol. 19, no. 9, p. 5701, May 2022, doi: 10.3390/ijerph19095701.
[9] P. A. Cohen, “Probiotic Safety—No Guarantees,” JAMA Intern. Med., vol. 178, no. 12, pp. 1577–1578, Dec. 2018, doi: 10.1001/jamainternmed.2018.5403.
[10] Z. T. Lewis et al., “Validating bifidobacterial species and subspecies identity in commercial probiotic products,” Pediatr. Res., vol. 79, no. 3, pp. 445–452, Mar. 2016, doi: 10.1038/pr.2015.244.
[11] D. Mazzantini, M. Calvigioni, F. Celandroni, A. Lupetti, and E. Ghelardi, “Spotlight on the Compositional Quality of Probiotic Formulations Marketed Worldwide,” Front. Microbiol., vol. 12, p. 693973, Jul. 2021, doi: 10.3389/fmicb.2021.693973.
[12] Health Canada, “Questions and Answers on Probiotics,” Government of Canada, Apr. 16, 2009. https://www.canada.ca/en/health-canada/services/food-nutrition/food-labelling/health-claims/questions-answers-probiotics.html (accessed Jun. 22, 2023).
[13] J. Suez et al., “Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT,” Cell, vol. 174, no. 6, pp. 1406-1423.e16, Sep. 2018, doi: 10.1016/j.cell.2018.08.047.
[14] V. Andresen, J. Gschossmann, and P. Layer, “Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial,” Lancet Gastroenterol. Hepatol., vol. 5, no. 7, pp. 658–666, Jul. 2020, doi: 10.1016/S2468-1253(20)30056-X.
[15] C. L. Garcia Rodenas, M. Lepage, C. Ngom-Bru, A. Fotiou, K. Papagaroufalis, and B. Berger, “Effect of Formula Containing Lactobacillus reuteri DSM 17938 on Fecal Microbiota of Infants Born by Cesarean-Section,” J. Pediatr. Gastroenterol. Nutr., vol. 63, no. 6, pp. 681–687, Dec. 2016, doi: 10.1097/MPG.0000000000001198.
[16] K. Korpela et al., “Probiotic supplementation restores normal microbiota composition and function in antibiotic-treated and in caesarean-born infants,” Microbiome, vol. 6, no. 1, p. 182, Oct. 2018, doi: 10.1186/s40168-018-0567-4.
[17] A. C. Ouwehand et al., “Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study,” Vaccine, vol. 32, no. 4, pp. 458–463, Jan. 2014, doi: 10.1016/j.vaccine.2013.11.053.
[18] W. E. Anthony et al., “Acute and persistent effects of commonly used antibiotics on the gut microbiome and resistome in healthy adults,” Cell Rep., vol. 39, no. 2, p. 110649, Apr. 2022, doi: 10.1016/j.celrep.2022.110649.
[19] H. C. Wastyk et al., “Gut-microbiota-targeted diets modulate human immune status,” Cell, vol. 184, no. 16, pp. 4137-4153.e14, Aug. 2021, doi: 10.1016/j.cell.2021.06.019.
[20] D. Kothari, S. Patel, and S.-K. Kim, “Probiotic supplements might not be universally-effective and safe: A review,” Biomed. Pharmacother. Biomedecine Pharmacother., vol. 111, pp. 537–547, Mar. 2019, doi: 10.1016/j.biopha.2018.12.104.
[21] R. L. Washburn, D. Sandberg, and M. A. Gazdik Stofer, “Supplementation of a single species probiotic does not affect diversity and composition of the healthy adult gastrointestinal microbiome,” Hum. Nutr. Metab., vol. 28, p. 200148, Jun. 2022, doi: 10.1016/j.hnm.2022.200148.
[22] D. A. Mills, J. B. German, C. B. Lebrilla, and M. A. Underwood, “Translating neonatal microbiome science into commercial innovation: metabolism of human milk oligosaccharides as a basis for probiotic efficacy in breast-fed infants,” Gut Microbes, vol. 15, no. 1, 2023, Accessed: Apr. 06, 2023. [Online]. Available: https://www.tandfonline.com/doi/full/10.1080/19490976.2023.2192458
[23] B. M. Henrick et al., “Colonization by B. infantis EVC001 modulates enteric inflammation in exclusively breastfed infants,” Pediatr. Res., vol. 86, no. 6, pp. 749–757, 2019, doi: 10.1038/s41390-019-0533-2.
[24] G. Casaburi et al., “Early-life gut microbiome modulation reduces the abundance of antibiotic-resistant bacteria,” Antimicrob. Resist. Infect. Control, vol. 8, p. 131, Aug. 2019, doi: 10.1186/s13756-019-0583-6.
[25] R. M. Duar et al., “Comparative Genome Analysis of Bifidobacterium longum subsp. infantis Strains Reveals Variation in Human Milk Oligosaccharide Utilization Genes among Commercial Probiotics,” Nutrients, vol. 12, no. 11, p. 3247, Oct. 2020, doi: 10.3390/nu12113247.
[26] P. S. La Rosa et al., “Patterned progression of bacterial populations in the premature infant gut,” Proc. Natl. Acad. Sci. U. S. A., vol. 111, no. 34, pp. 12522–12527, Aug. 2014, doi: 10.1073/pnas.1409497111.
[27] J. E. Koenig et al., “Succession of microbial consortia in the developing infant gut microbiome,” Proc. Natl. Acad. Sci., vol. 108, pp. 4578–4585, Mar. 2011, doi: 10.1073/pnas.1000081107.
[28] B. Poindexter et al., “Use of Probiotics in Preterm Infants,” Pediatrics, vol. 147, no. 6, p. e2021051485, Jun. 2021, doi: 10.1542/peds.2021-051485.
[29] D. Merenstein et al., “Emerging issues in probiotic safety: 2023 perspectives,” Gut Microbes, vol. 15, no. 1, p. 2185034, 2023, doi: 10.1080/19490976.2023.2185034.
[30] S. Bajorek et al., “B. infantis EVC001 Is Well-Tolerated and Improves Human Milk Oligosaccharide Utilization in Preterm Infants in the Neonatal Intensive Care Unit,” Front. Pediatr., vol. 9, p. 795970, 2021, doi: 10.3389/fped.2021.795970.
[31] C. Milani et al., “The First Microbial Colonizers of the Human Gut: Composition, Activities, and Health Implications of the Infant Gut Microbiota,” Microbiol. Mol. Biol. Rev. MMBR, vol. 81, no. 4, pp. e00036-17, Dec. 2017, doi: 10.1128/MMBR.00036-17.
[32] “Antibiotic Resistance Threats in the United States, 2019,” Centers for Disease Control, 2019. https://www.cdc.gov/drugresistance/biggest-threats.html (accessed Jun. 22, 2023).
[33] A. Crits-Christoph, H. A. Hallowell, K. Koutouvalis, and J. Suez, “Good microbes, bad genes? The dissemination of antimicrobial resistance in the human microbiome,” Gut Microbes, vol. 14, no. 1, p. 2055944, Dec. 2022, doi: 10.1080/19490976.2022.2055944.
[34] E. A. Franzosa et al., “Identifying personal microbiomes using metagenomic codes,” Proc. Natl. Acad. Sci., vol. 112, no. 22, pp. E2930–E2938, Jun. 2015, doi: 10.1073/pnas.1423854112.
[35] M. E. Sanders, D. J. Merenstein, G. Reid, G. R. Gibson, and R. A. Rastall, “Probiotics and prebiotics in intestinal health and disease: from biology to the clinic,” Nat. Rev. Gastroenterol. Hepatol., vol. 16, no. 10, pp. 605–616, Oct. 2019, doi: 10.1038/s41575-019-0173-3.
[36] “Food as Medicine: Prebiotic Foods,” Children’s Hospital of Philadelphia, Dec. 21, 2022. https://www.chop.edu/health-resources/food-medicine-prebiotic-foods (accessed Jun. 22, 2023).